Chemotherapy can raise blood sugar to the point of triggering new-onset diabetes or pushing someone with borderline glucose levels into a full diagnosis. In studies of colorectal and breast cancer patients, those who received chemotherapy had roughly 24 to 30 percent higher risk of developing type 2 diabetes in the years following treatment. But “chemo” is only part of the picture; the steroids bundled with many regimens, newer targeted drugs, and immunotherapy agents each carry their own distinct pathways to disrupted blood sugar, and the risk profile changes depending on which combination you receive.
How Chemotherapy Disrupts Blood Sugar
Several mechanisms link cancer treatment to rising glucose. Conventional cytotoxic chemotherapy drugs can damage the insulin-producing beta cells in the pancreas, promote insulin resistance in muscle and fat tissue, and alter hormones that regulate appetite and weight. A 2021 review in Endocrine Practice identified three key drivers: enhanced insulin resistance, increased glucose production by the liver, and direct beta-cell dysfunction.1Endocrine Practice. Can Chemo Cause Diabetes? Risks, Signs, and Management These effects can appear during active treatment and sometimes persist for years after the last infusion.
Not every chemotherapy drug carries the same level of risk. L-asparaginase, a drug commonly used in acute lymphoblastic leukemia, has been linked to acute pancreatitis and even diabetic ketoacidosis, a dangerous metabolic emergency, particularly when combined with prednisone.2PubMed Central. Acute Pancreatitis and Diabetic Ketoacidosis following L-Asparaginase/Prednisone Therapy in Acute Lymphoblastic Leukemia Meanwhile, many standard regimens for breast, colorectal, and blood cancers include drugs that gradually erode glucose control over weeks to months rather than triggering a sudden crisis.
The Steroid Problem
If you’ve undergone chemo, there’s a good chance you also received high-dose glucocorticoids like dexamethasone or prednisone. These steroids are given to reduce nausea, lower inflammation, and in some blood cancers serve as a direct anti-cancer agent. They are also among the most reliable ways to spike someone’s blood sugar. Glucocorticoids ramp up glucose production in the liver and make cells throughout the body less responsive to insulin, a double hit that can send fasting glucose soaring within days of starting a cycle.
A large population-based study of over 15,000 people with hematologic cancers and no prior diabetes found that glucocorticoid exposure during chemotherapy increased the risk of new-onset diabetes by about 29 percent and new-onset hyperglycemia by 28 percent. Among patients with leukemia specifically, over 18 percent developed new-onset hyperglycemia, and about 7 percent were diagnosed with diabetes.3Canadian Journal of Diabetes. Determining the Associations Between Glucocorticoid Use During Hematologic Chemotherapy Treatment and New-onset Diabetes and Hyperglycemia and Mortality: A Population-based Cohort Study What makes steroid-induced hyperglycemia tricky is its timing: blood sugar tends to peak in the afternoon and evening on steroid dosing days, so a fasting morning glucose test can look normal while your sugar is dangerously high the rest of the day.
Targeted Therapies and the PI3K Pathway
Beyond conventional chemo and steroids, a newer class of drugs creates its own glucose headaches. Drugs that target the PI3K-AKT-mTOR signaling pathway are used in certain breast cancers, lymphomas, and other solid tumors. This pathway plays a central role in how your cells respond to insulin, so blocking it predictably disrupts glucose metabolism.
In a study of patients on early-phase clinical trials, high-grade hyperglycemia (the kind that requires medical intervention) was significantly more common among those receiving PI3K-AKT-mTOR pathway inhibitors compared to controls receiving other treatments. While some degree of elevated blood sugar was common in both groups, severe hyperglycemia occurred in about 7 percent of the targeted-therapy group versus none in controls. AKT inhibitors and multikinase inhibitors carried the highest rates.4Nature / British Journal of Cancer. Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials Patients on these drugs generally need more frequent glucose monitoring than those on standard chemotherapy.
Immunotherapy and Sudden-Onset Diabetes
Immune checkpoint inhibitors, the blockbuster immunotherapy drugs used in melanoma, lung cancer, and a growing list of other cancers, can trigger an entirely different form of diabetes. Rather than gradually wearing down insulin sensitivity, these drugs can provoke the immune system to attack and destroy the pancreas’s beta cells, mimicking type 1 diabetes. This form comes on fast and can be severe.
A review of over 14,000 patients treated with checkpoint inhibitors identified three distinct phenotypic categories of immunotherapy-induced diabetes. Some patients presented with fulminant disease, meaning rapid total loss of insulin production. Others had a more gradual onset with some preserved pancreatic function. Autoantibodies against beta cells were present in some but not all patients, making it harder to predict who would be affected.5JAMA Oncology. Identification of Immune Checkpoint Inhibitor–Induced Diabetes
A case that illustrates the danger: a 51-year-old woman with metastatic melanoma developed diabetic ketoacidosis just three weeks after starting combination immunotherapy with nivolumab and ipilimumab. She had normal blood sugar and no metabolic issues before treatment. She arrived vomiting and profoundly weak, with blood gas results showing severe acidosis and a blood glucose of 32.5 mmol/L (about 585 mg/dL). Testing confirmed her pancreas had essentially stopped making insulin.6PubMed Central. Immune Checkpoint Inhibitor-Induced Diabetes Presenting As Diabetic Ketoacidosis: A Case Report Unlike steroid-related hyperglycemia, which often improves when the steroid dose drops, immunotherapy-induced diabetes is frequently permanent and requires lifelong insulin therapy.
Among patients who developed checkpoint inhibitor diabetes and progressed to diabetic ketoacidosis, the average time from starting therapy to the event was about 140 days. Those who developed DKA had significantly higher rates of diabetes-related hospitalization and worse survival compared to checkpoint inhibitor patients who did not develop diabetes.7Diabetes. 1669-P: Immune Checkpoint Inhibitor Induced Diabetes and Diabetic Ketoacidosis
Who Is Most at Risk
Not everyone receiving cancer treatment will develop diabetes, and some people are substantially more vulnerable than others. The most consistent risk factors are the same ones that predict diabetes in the general population: older age, higher body weight, a family history of diabetes, and belonging to racial or ethnic groups with elevated baseline rates. What cancer treatment does is layer additional metabolic stress on top of those existing vulnerabilities.
A systematic review of new-onset type 2 diabetes after cancer diagnosis found that colorectal cancer patients treated with chemotherapy had about 30 percent higher risk of developing diabetes within one to five years. For postmenopausal women with breast cancer, the elevated risk appeared after roughly two years from diagnosis, and those who received adjuvant chemotherapy specifically had about 24 percent higher risk.8PubMed Central. New onset of type 2 diabetes as a complication after cancer diagnosis: A systematic review The risk was highest in the years immediately following treatment and gradually declined, suggesting that treatment itself was a precipitating factor rather than a permanent metabolic change in every case.
The type of treatment matters as well. Patients who receive glucocorticoids alongside their chemotherapy carry additional risk, as do those on prolonged courses of targeted therapies that interfere with insulin signaling. Radiation to the abdomen or pancreatic area can compound the problem by directly damaging insulin-producing tissue.
Recognizing the Signs During Treatment
Spotting new diabetes during chemotherapy is harder than it sounds, because many of the symptoms overlap with ordinary side effects of treatment. Fatigue, increased thirst, frequent urination, blurred vision, and nausea can all be chalked up to chemo itself. Patients who develop steroid-induced hyperglycemia often notice they’re urinating more frequently and feeling excessively thirsty in the hours after a steroid dose, but these symptoms can be intermittent enough to miss.
For immunotherapy-induced diabetes, the onset can be dramatic. Nausea, vomiting, abdominal pain, and extreme weakness might develop over days. Because many patients and even some clinical teams associate those symptoms with the cancer treatment itself, the underlying metabolic emergency can be missed until it becomes severe. If you’re on a checkpoint inhibitor and experience sudden-onset thirst, unintended weight loss, or gastrointestinal symptoms that feel different from your usual treatment side effects, it’s worth requesting an urgent blood glucose and ketone check.
How Oncologists Monitor for It
Practices vary, but a cross-sectional study of oncologists found that fasting blood glucose was the most commonly used parameter for monitoring patients on curative-intent chemotherapy, used by about 96 percent of respondents, followed by HbA1c at about 79 percent. For patients on palliative chemotherapy, approaches shifted toward random blood glucose checks, patient-reported readings, and even continuous glucose monitoring in some settings.9PubMed Central. Optimal hyperglycemia thresholds in patients undergoing chemotherapy: a cross sectional study of oncologists’ practices
Continuous glucose monitoring is increasingly being studied in cancer populations. A pilot trial in early-stage breast cancer patients tracked glucose levels over the first 24 weeks of chemotherapy and found that changes in HbA1c from baseline varied significantly depending on whether patients started treatment with normal glucose, prediabetes, or existing diabetes.10Journal of Clinical Oncology. Continuous glucose monitoring and rates of hyperglycemia during chemotherapy for early-stage breast cancer The appeal of continuous monitors is that they catch the afternoon and evening glucose spikes that a single morning blood draw misses, which is particularly important for patients on intermittent steroid dosing.
Why Uncontrolled Blood Sugar Matters for Cancer Outcomes
High blood sugar during cancer treatment is not just an inconvenient side effect. There’s growing evidence that hyperglycemia can actively work against cancer treatment. Elevated glucose may fuel tumor growth, reduce the effectiveness of certain chemotherapy drugs, and promote resistance to apoptosis (the self-destruction mechanism cells use to eliminate damaged or cancerous tissue).11PubMed Central. Hyperglycemia, a neglected factor during cancer progression
The clinical numbers back this up. In a study of cancer patients receiving glucocorticoids with chemotherapy, those with a diabetes history had a one-year survival rate of about 67 percent compared with roughly 78 percent for those without diabetes. Patients who had at least one glucose reading above 300 mg/dL after chemotherapy fared even worse, with one-year survival around 61 percent. After adjusting for cancer stage, age, and sex, diabetes history nearly doubled the odds of dying within a year and increased infection risk by about 68 percent.12Journal of Clinical Oncology. Impact of diabetes and hyperglycemia on health care utilization, infection risk, and survival in patients with cancer receiving glucocorticoids with chemotherapy These findings suggest that actively managing blood sugar during treatment isn’t just about comfort; it may directly affect how well the cancer treatment works.
In pancreatic cancer specifically, patients with diabetes at the time of surgical resection had larger tumors on average and, after statistical adjustment, a roughly 19 percent higher risk of death compared to those without diabetes.13Nature. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer
Managing Blood Sugar During and After Treatment
Management depends heavily on what’s driving the hyperglycemia. Steroid-induced blood sugar spikes are often managed with short-acting insulin timed to the steroid dosing schedule. Because steroids tend to raise glucose most in the afternoon and evening, a single morning dose of long-acting insulin may not be enough; many patients need a regimen that accounts for the steroid’s pharmacologic peak. When the steroid course ends, glucose often improves, and insulin can sometimes be tapered or stopped.
For patients with pre-existing type 2 diabetes, the challenge is that chemotherapy itself can make oral diabetes medications harder to tolerate. Nausea, vomiting, reduced food intake, and changes in kidney function during treatment may require temporary switches to insulin or dose adjustments of existing medications. Your oncology and endocrinology teams need to communicate about these changes, because a dose that’s correct during a treatment week may cause dangerous low blood sugar during a recovery week when you’re eating normally again.
Immunotherapy-induced diabetes, where the immune system has destroyed the beta cells, almost always requires lifelong insulin. The management is more similar to type 1 diabetes than type 2, regardless of the patient’s age or prior metabolic history. Patients need to learn carbohydrate counting, insulin dosing, and how to recognize hypoglycemia, essentially absorbing years’ worth of diabetes self-management education at a time when they’re also dealing with active cancer treatment.
One qualitative study captured the experience well: patients with type 2 diabetes who started chemotherapy described profound confusion about whether their symptoms were from the cancer treatment or from worsening blood sugar. Over time, they developed trial-and-error strategies, learning to recognize their own patterns of blood sugar fluctuation around treatment cycles and adjusting diet, activity, and medication timing accordingly.14Asia-Pacific Journal of Oncology Nursing. A qualitative study of blood glucose and side effect self-management among patients with type 2 diabetes undergoing chemotherapy for cancer This kind of self-management learning curve is real and under-discussed. If you’re navigating both cancer treatment and diabetes, asking your team for a referral to a diabetes educator early in treatment, rather than waiting until things go sideways, can make a meaningful difference.
Childhood Cancer Survivors Face a Growing Problem
The long-term metabolic consequences of cancer treatment are especially concerning for people treated as children. Despite improvements in survival and a general reduction in many late effects of childhood cancer treatment, the cumulative incidence of diabetes among childhood cancer survivors has actually increased over recent decades. Treatment-related exposures like chemotherapy and radiation may compound established diabetes risk factors such as obesity, older age, and racial or ethnic background in ways that are more than simply additive.15PubMed Central. Diabetes in childhood cancer survivors: emerging concepts in pathophysiology and future directions
A key part of why this population is vulnerable involves body composition. Chemotherapy and radiation can alter both skeletal muscle and fat tissue, which are important endocrine organs involved in glucose regulation. Disruptions to the crosstalk between muscle and fat tissue during childhood development may set up metabolic dysfunction that manifests years or decades later.16PubMed Central. The role of body composition in the development of diabetes mellitus among childhood cancer survivors, and novel intervention strategies to mitigate diabetes risk For adult survivors of childhood cancer, this means that routine metabolic screening, including periodic glucose and HbA1c testing, should be part of long-term survivorship care even if you feel healthy and maintain a normal weight.
Disparities in Diabetes Care for Cancer Patients
Even when diabetes is recognized, access to the best treatments is not equal across all cancer patients. A recent analysis of over 200,000 cancer patients examined prescribing rates for GLP-1 receptor agonists, a class of drugs now considered among the most effective for type 2 diabetes and obesity management. Cancer patients were significantly less likely to receive these medications than matched non-cancer patients, and the gap actually widened during a period of national drug shortages. Black cancer patients had persistently lower prescribing rates than White patients, and Asian patients experienced newly emergent disparities during the shortage period that had not been present before.17JCO Oncology Practice. Disparities in access of GLP-1 receptor agonists in cancer patients with obesity or type 2 diabetes: A cascade-of-care analysis across the semaglutide shortage timeline. Fewer than 1 percent of cancer patients maintained persistent use of these medications.
These numbers point to a structural gap. Cancer patients with diabetes need both oncologic and metabolic care, and when those two worlds don’t communicate well, or when drug supply chains tighten, cancer patients tend to lose out. If you have both cancer and diabetes, or you develop diabetes during treatment, it’s worth explicitly raising the question of metabolic management with your oncology team rather than assuming it will be addressed as part of your cancer care. In many settings, a referral to endocrinology is needed and doesn’t happen automatically.